Turning Point Brands (TPB) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
The 2025 Annual Meeting will be held virtually on May 8, 2025, with stockholders able to participate and vote online using a control number from their proxy card.
Key proposals include electing ten directors, amending the Certificate of Incorporation to limit officer liability, ratifying KPMG LLP as the new independent auditor, and an advisory vote on executive compensation.
Only stockholders of record as of March 7, 2025, are entitled to vote; 17,867,759 shares are outstanding, with a quorum set at 8,933,880 shares.
The Board recommends voting in favor of all proposals.
Voting matters and shareholder proposals
Proposals: election of ten directors, amendment to limit officer liability, ratification of KPMG LLP as auditor, and advisory say-on-pay vote.
The amendment to limit officer liability aligns with recent Delaware law changes and aims to attract and retain qualified officers.
KPMG LLP is proposed as the new auditor, replacing RSM US LLP, to ensure continued independence and meet evolving company needs.
Shareholder proposals for the 2026 meeting must be submitted by November 24, 2025, to be included in the proxy statement.
Board of directors and corporate governance
The Board is expanding from nine to ten members, with Kathleen Shanahan nominated for the new seat.
The Board includes a mix of experienced executives, with a majority self-identifying as women or people of color.
Board leadership is separated between the Executive Chairman and CEO, with a Lead Independent Director ensuring independent oversight.
Three standing committees: Audit, Compensation, and Nominating & Governance, all composed of independent directors.
Directors receive annual cash retainers and RSUs; additional fees are paid for committee roles.
Latest events from Turning Point Brands
- Modern Oral sales soared 128% YoY, boosting revenue but profits fell on higher investment.TPB
Q2 2026 - Modern Oral net sales jumped 133%, driving Q1 growth and higher FY 2026 guidance.TPB
Q1 2026 - All board nominees, auditor ratification, and executive compensation were approved.TPB
AGM 2026 - Annual meeting to vote on directors, auditor, and executive pay, with emphasis on diversity and governance.TPB
Proxy filing - Modern Oral net sales jumped 266% in Q4, fueling 29% revenue growth and a strong 2026 outlook.TPB
Q4 2025 - Board recommends voting for all proposals, emphasizing diversity and governance improvements.TPB
Proxy Filing - Q3 2024 saw double-digit profit growth, raised guidance, and expanded share buybacks.TPB
Q3 2024 - Q2 sales and EBITDA rose, guidance increased, and net income jumped 31% on strong segment growth.TPB
Q2 2024 - FY2024 net sales up 11% and EBITDA up 12%, with strong modern oral and core brand growth.TPB
Q4 2024